Residue G346 in transmembrane segment six is involved in inter-domain communication in P-glycoprotein

Biochemistry

Volumn 46, Issue 35, 2007, Pages 9899-9910

  Storm, Janet ^a   O'Mara, Megan L ^c   Crowley, Emily H ^a   Peall, Jonathan ^a   Tieleman, D Peter ^c   Kerr, Ian D ^b   Callaghan, Richard ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; DRUG DELIVERY; ENERGY UTILIZATION; HYDROLYSIS; MOLECULAR DYNAMICS; MUTAGENESIS; NUCLEOTIDES;

CYSTEINE-SCANNING MUTAGENESIS; INTER-DOMAIN COMMUNICATION; MULTIDRUG TRANSPORT; TRANSMEMBRANE SEGMENT SIX;

GLYCOPROTEINS;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; CYSTEINE; GLYCOPROTEIN P;

ANIMAL CELL; ARTICLE; DRUG TRANSPORT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROLYSIS; MOLECULAR INTERACTION; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; STEREOCHEMISTRY;

ADENOSINE TRIPHOSPHATASES; ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; BINDING SITES; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; CELL MEMBRANE; CYSTEINE; GLYCINE; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; P-GLYCOPROTEIN; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548507482     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi700447p     Document Type: Article

References (55)

1. Chan, H. S., Haddad, G., Thorner, P. S., DeBoer, G., Lin, Y. P., Ondrusek, N., Yeger, H., and Ling, V. (1991) P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma, N. Engl. J. Med. 325, 1608-1614.
2. van den Heuvel-Eibrink, M. M., Sonneveld, P., and Pieters, R. (2000) The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia, Int. J. Clin. Pharmacol. Ther. 38, 94-110.
3. Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., and Bertino, J. R. (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites, Proc. Natl. Acad. Sci. U.S.A. 86, 695-698.
4. van der Valk, P., van Kalken, C. K., Ketelaars, H., Broxterman, H. J., Scheffer, G., Kuiper, C. M., Tsuruo, T., Lankelma, J., Meijer, C. J., Pinedo, H. M., et al. (1990) Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule, Ann. Oncol. 1, 56-64.
5. Cascorbi, I. (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs, Pharmacol. Ther. 112, 457-473.
6. Dey, S., Ramachandra, M., Pastan, I., Gottesman, M. M., and Ambudkar, S. V. (1997) Evidence for two nonidentical drug-interaction sites in the human P- glycoprotein, Proc. Natl. Acad. Sci. U.S.A. 94, 10594-10599.
7. Martin, C., Berridge, G., Higgins, C. F., Mistry, P., Charlton, P., and Callaghan, R. (2000) Communication between multiple drug binding sites on P-glycoprotein, Mol. Pharmacol. 58, 624-632.
8. Pascaud, C., Garrigos, M., and Orlowski, S. (1998) Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents, Biochem. J. 333, 351-358.
9. Shapiro, A. B., and Ling, V. (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities, Eur. J. Biochem. 250, 130-137.
10. Bruggeman, E. P., Germann, U. A., Gottesman, M. M., and Pastan, I. (1989) Two different regions of phosphoglycoprotein are photoaffinity labeled by azidopine, J. Biol. Chem. 264, 15483-15488.
11. Ecker, G. F., Csaszar, E., Kopp, S., Plagens, B., Holzer, W., Ernst, W., and Chiba, P. (2002) Identification of ligand-binding regions of P-glycoprotein by activated-pharmacophore photoaffinity labeling and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry, Mol. Pharmacol. 61, 637-648.
12. Greenberger, L. M. (1993) Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12, J. Biol. Chem. 268, 11417-11425.
13. Pleban, K., Kopp, S., Csaszar, E., Peer, M., Hrebicek, T., Rizzi, A., Ecker, G. F., and Chiba, P. (2005) P-glycoprotein substrate binding domains are located at the transmembrane domain/ transmembrane domain interfaces: a combined photoaffinity labeling-protein homology modeling approach, Mol. Pharmacol. 67, 365-374.
14. Taylor, A. M., Storm, J., Soceneantu, L., Linton, K. J., Gabriel, M., Martin, C., Woodhouse, J., Blott, E., Higgins, C. F., and Callaghan, R. (2001) Detailed characterization of cysteine-less P-glycoprotein reveals subtle pharmacological differences in function from wild-type protein, Br. J. Pharmacol. 134, 1609-1618.
15. al-Shawi, M. K., Urbatsch, I. L., and Senior, A. E. (1994) Covalent inhibitors of P-glycoprotein ATPase activity, J. Biol. Chem. 269, 8986-8992.
16. Hrycyna, C. A., Ramachandra, M., Germann, U. A., Cheng, P. W., Pastan, I., and Gottesman, M. M. (1999) Both ATP sites of human P-glycoprotein are essential but not symmetric, Biochem. 38, 13887-13899.
17. Loo, T. W., and Clarke, D. M. (1995) Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug- stimulated ATPase activity, J. Biol. Chem. 270, 22957-22961.
18. Callaghan, R., Ford, R. C., and Kerr, I. D. (2006) The translocation mechanism of P-glycoprotein, FEBS Lett. 580, 1056-1063.
19. Devine, S. E., Ling, V., and Melera, P. W. (1992) Amino acid substitutions in the sixth transmembrane domain of P- glycoprotein alter multidrug resistance, Proc. Natl. Acad. Sci U.S.A. 89, 4564-4568.
20. Loo, T. W., and Clarke, D. M. (1994) Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P- glycoprotein, Biochemistry 33, 14049-14057.
21. Loo, T. W., and Clarke, D. M. (1996) Inhibition of oxidative cross-linking between engineered cysteine residues at positions 332 in predicted transmembrane segments (TM) 6 and 975 in predicted TM12 of human P-glycoprotein by drug substrates, J. Biol Chem. 271, 27482-27487.
22. Ma, J. F., Grant, G., and Melera, P. W. (1997) Mutations in the sixth transmembrane domain of P-glycoprotein that alter the pattern of cross-resistance also alter sensitivity to cyclosporin A reversal, Mol. Pharmacol. 51, 922-930.
23. Song, J., and Melera, P. W. (2001) Further characterization of the sixth transmembrane domain of Pgpl by site-directed mutagenesis, Cancer Chemother. Pharmacol. 48, 339-46.
24. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2003) Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding, J. Biol. Chem. 278, 13603-13606.
25. Loo, T. W., and Clarke, D. M. (1997) Identification of residues in the drug-binding site of human P- glycoprotein using a thiolreactive substrate, J. Biol. Chem. 272, 31945-31948.
26. Loo, T. W., and Clarke, D. M. (1999) Identification of residues in the drug-binding domain of human P-glycoprotein. Analysis of transmembrane segment 11 by cysteine-scanning mutagenesis and inhibition by dibromobimane, J. Biol. Chem. 274, 35388-35392.
27. Rothnie, A., Storm, J., Campbell, J., Linton, K. J., Kerr, I. D., and Callaghan, R. (2004) The topography of transmembrane segment six is altered during the catalytic cycle of P-glycoprotein, J. Biol. Chem. 279, 34913-34921.
28. Loo, T. W., and Clarke, D. M. (2001) Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil, J. Biol. Chem. 276, 14972-14979.
29. Rothnie, A., Storm, J., McMahon, R., Taylor, A., Kerr, I. D., and Callaghan, R. (2005) The coupling mechanism of P-glycoprotein involves residue L339 in the sixth membrane spanning segment, FEBS Lett. 579, 3984-3990.
30. Rosenberg, M. F., Callaghan, R., Modok, S., Higgins, C. F., and Ford, R. C. (2005) Three-dimensional Structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state, J. Biol. Chem. 280, 2857-2862.
31. Rosenberg, M. F., Kamis, A. B., Callaghan, R., Higgins, C. F., and Ford, R. C. (2003) Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding, J. Biol. Chem. 278, 8294-8299.
32. Rosenberg, M. F., Velarde, G., Ford, R. C., Martin, C., Berridge, G., Kerr, I. D., Callaghan, R., Schmidlin, A., Wooding, C., Linton, K. J., and Higgins, C. F. (2001) Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle, EMBO J. 20, 5615-5625.
33. Dawson, R. J., and Locher, K. P. (2006) Structure of a bacterial multidrug ABC transporter, Nature 443, 180-185.
34. Stenham, D. R., Campbell, J. D., Sansom, M. S., Higgins, C. F., Kerr, I. D., and Linton, K. J. (2003) An atomic detail model for the human ATP binding cassette transporter P-glycoprotein derived from disulfide cross-linking and homology modeling, FASEB J. 17, 2287-2289.
35. Chifflet, S., Chiesa, U. T. R., and Tolosa, S. (1988) A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein: application to lens ATPases, Anal. Biochem. 168, 1-4.
36. Gabriel, M. P., Storm, J., Rothnie, A., Taylor, A. M., Linton, K. J., Kerr, I. D., and Callaghan, R. (2003) Communication between the nucleotide binding domains of P-glycoprotein occurs via conformational changes that involve residue 508, Biochemistry 42, 7780-7789.
37. Notredame, C., Higgins, D. G., and Heringa, J. (2000) T-Coffee: a novel method for fast and accurate multiple sequence alignment, J. Mol. Biol. 302, 205-217.
38. Thompson, J. D., Higgins, D. G., and Gibson, T. J. (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice, Nucleic Acids Res. 22, 4673-4680.
39. Rost, B., Liu, J., Nair, R., Wrzeszczynski, K. O., and Ofran, Y. (2003) Automatic prediction of protein function, Cell. Mol. Life Sci. 60, 2637-2650.
40. Sali, A., Potterton, L., Yuan, F., van Vlijmen, H., and Karplus, M. (1995) Evaluation of comparative protein modeling by MODELLER, Proteins 23, 318-326.
41. Laskowski, R. A., Moss, D. S., and Thornton, J. M. (1993) Mainchain bond lengths and bond angles in protein structures, J. Mol. Biol. 231, 1049-1067.
42. Vriend, G. (1990) WHAT IF: a molecular modeling and drug design program, J. Mol. Graphics 8(1): 52-56, 29.
43. Rothnie, A., Theron, D., Soceneantu, L., Martin, C., Traikia, M., Berridge, G., Higgins, C. F., Devaux, P. F., and Callaghan, R. (2001) The importance of cholesterol in maintenance of P-glycoprotein activity and its membrane perturbing influence, Eur. Biophys. J. 30, 430-442.
44. Senes, A., Gerstein, M., and Engelman, D. M. (2000) Statistical analysis of amino acid patterns in transmembrane helices: the GxxxG motif occurs frequently and in association with beta-branched residues at neighboring positions, J. Mol. Biol. 296, 921-936.
45. Russ, W. P., and Engelman, D. M. (2000) The GxxxG motif: a framework for transmembrane helix-helix association, J. Mol. Biol. 296, 911-919.
46. Ferry, D. R., Russell, M. A., and Cullen, M. H. (1992) P-glycoprotein possesses a 1,4-dihydropyridine selective drug acceptor site which is allosterically coupled to a vinca alkaloid selective binding site, Biochem. Biophys. Res. Commun. 188, 440-445.
47. Locher, K. P., Lee, A. T., and Rees, D. C. (2002) The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism, Science 296, 1091-1098.
48. Berridge, G., Walker, J. A., Callaghan, R., and Kerr, I. D. (2003) The nucleotide-binding domains of P-glycoprotein. Functional symmetry in the isolated domain demonstrated by N-ethylmaleimide labeling, Eur. J. Biochem. 270, 1483-1492.
49. Davidson, A. L., and Nikaido, H. (1991) Purification and characterization of the membrane-associated components of the maltose transport system from Escherichia coli, J. Biol. Chem. 266, 8946-8951.
50. Ko, Y. H., and Pedersen, P. L. (1995) The first nucleotide binding fold of the cystic fibrosis transmembrane conductance regulator can function as an active ATPase, J. Biol. Chem. 270, 22093-22096.
51. Liu, P.-Q., and Ames, G. F.-L. (1998) In vitro disassembly and reassembly of an ABC transporter, the histidine permease, Proc. Natl. Acad. Sci. U.S.A. 95, 3495-3500.
52. Morbach, S., Tebbe, S., and Schneider, E. (1993) The ATP-binding cassette (ABC) transporter for maltose/maltodextrins of Salmonella typhimurium, J. Biol. Chem. 268, 18617-18621.
53. Nikaido, K., Liu, P.-Q., and Ames, G. F.-L. (1997) Purification and characterization of HisP, the ATP-binding subunit of a traffic ATPase (ABC transporter), the histidine permease of Salmonella typhimurium, J. Biol. Chem. 272, 27745-27752.
54. Tombline, G., Muharemagic, A., White, L. B., and Senior, A. E. (2005) Involvement of the "occluded nucleotide conformation" of p-glycoprotein in the catalytic pathway, Biochemistry 44, 12879-12886.
55. Jones, P. M., and George, A. M. (2002) Mechanism of ABC transporters: a molecular dynamics simulation of a well characterized nucleotide-binding subunit, Proc. Natl. Acad. Sci. U.S.A. 99, 12639-12644.